Understanding Leukemia’s Impact on Your DNA

Understanding Leukemia’s Impact on Your DNA | Research in a Minute


Typically, cancer patients—whether they have lung cancer or leukemia—are treated with chemotherapy. Chemo’s aim is to attack harmful cancer cells; however, it also kills normal, healthy cells, leaving patients susceptible to infection and other harmful side effects. What if there were a way to specifically target cancer cells, without putting healthy cells at risk? As an Associate Investigator at Versiti Blood Research Institute, Dr. Pulikkan studies CEBPA, a gene in the human body that is mutated in acute myeloid leukemia. Little is known about CEBPA mutations in leukemia, and very few labs are working on it. Dr. Pulikkan is working hard to understand how it mutates and causes leukemia. 

About the expert: John A. Pulikkan, PhD is an Associate Investigator at Versiti Blood Research Institute. In addition, he is an Assistant Professor of Cell Biology, Neurobiology and Anatomy at Medical College of Wisconsin and a Member of the Medical College of Wisconsin Cancer Center. 

 
Join Versiti Blood Research Institute
Versiti Blood Research Institute, located in Milwaukee, Wisconsin, includes basic and clinical researchers in a variety of blood health fields.
 
Our Experts
Research investigators, postdoctoral fellows and laboratory staff at Versiti Blood Research Institute and Diagnostic Laboratories.
 
John A. Pulikkan, PhD
Dr. Pulikkan is an associate investigator at Versiti Blood Research Institute who studies cell development and how it causes acute myeloid leukemia (AML).
 
Versiti Blood Research Institute
Versiti Blood Research Institute investigators study blood disorders like hemophilia, blood cancers like leukemia, and other blood diseases.